Dr Reddy’s has secured European Commission approval for AVT03, its biosimilar version of Prolia and Xgeva—medicines used to treat osteoporosis and prevent bone complications in cancer patients.
Dr Reddy’s has secured European Commission approval for AVT03, its biosimilar version of Prolia and Xgeva—medicines used to treat osteoporosis and prevent bone complications in cancer patients.